This three-part webinar series reviews the key considerations for design and conduct of a development plan for a monoclonal antibody (mAb) product.

Autoimmune diseases such as ulcerative colitis require chronic treatment that often causes systemic immunosuppression, increasing long-term cancer and infection risk. Reducing systemic side effects with localized treatment would greatly benefit patients.

Dry powder inhalers are gaining increasing momentum for drug delivery to the lungs. One of the most used and flexible delivery technologies are capsule-based dry powder inhalers

Bringing a drug from discovery to market is an expensive and time-consuming business. Every drug that fails comes with a cost which could be both reputational and financial. Keeping your development program on track is therefore critical to success.

Better target validation is a key driver of better productivity in drug discovery. The RNA-guided nucleases, exemplified by Cas9, represent a powerful new approach to understanding gene function and, in principle, to reveal the next generation of therapeutic targets. But how well does this technology work in practice?

Delineation of the intra-tumor microenvironment in a dynamic, spatiotemporal setting is critical for investigating the activity and efficacy of candidate oncology drugs. The majority of solid cancers contain unorganized, highly complex microenvironments wherein a dysregulated phenotype impacts treatment outcomes at a personalized level.